These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 15995924)

  • 1. Clinical microbiology and infectious diseases. Management of fungal infections.
    Arikan S
    IDrugs; 2001 Jul; 4(7):746-9. PubMed ID: 15995924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New agents for the treatment of systemic fungal infections--current status.
    Arikan S; Rex JH
    Expert Opin Emerg Drugs; 2002 May; 7(1):3-32. PubMed ID: 15989533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts.
    Metcalf SC; Dockrell DH
    J Infect; 2007 Oct; 55(4):287-99. PubMed ID: 17697716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosis and therapy of fungal infection in patients with leukemia--new drugs and immunotherapy.
    Anaissie EJ
    Best Pract Res Clin Haematol; 2008 Dec; 21(4):683-90. PubMed ID: 19041608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Newer antifungal agents for invasive fungal infections in patients with haematological malignancy.
    Rogers TR; Frost S
    Br J Haematol; 2009 Mar; 144(5):629-41. PubMed ID: 19120371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antifungal drug discovery, six new molecules patented after 10 years of feast: why do we need new patented drugs apart from new strategies?
    Krcmery V; Kalavsky E
    Recent Pat Antiinfect Drug Discov; 2007 Nov; 2(3):182-7. PubMed ID: 18221175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human mycoses and advances in antifungal therapy.
    Fromtling RA
    Drug News Perspect; 2001 Apr; 14(3):181-92. PubMed ID: 12819825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contribution of new diagnostic approaches to antifungal treatment plans in high-risk haematology patients.
    Einsele H; Loeffler J
    Clin Microbiol Infect; 2008 May; 14 Suppl 4():37-45. PubMed ID: 18430128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact.
    Kanafani ZA; Perfect JR
    Clin Infect Dis; 2008 Jan; 46(1):120-8. PubMed ID: 18171227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent approaches to antifungal therapy for invasive mycoses.
    Mathew BP; Nath M
    ChemMedChem; 2009 Mar; 4(3):310-23. PubMed ID: 19170067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antifungal agents.
    Ryder NS
    IDrugs; 1999 Dec; 2(12):1253-5. PubMed ID: 16113946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances and challenges in the treatment of invasive fungal infections.
    Shao PL; Huang LM; Hsueh PR
    Int J Antimicrob Agents; 2007 Dec; 30(6):487-95. PubMed ID: 17961990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of invasive fungal infections in cancer patients--recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).
    ; Böhme A; Ruhnke M; Buchheidt D; Cornely OA; Einsele H; Enzensberger R; Hebart H; Heinz W; Junghanss C; Karthaus M; Krüger W; Krug U; Kubin T; Penack O; Reichert D; Reuter S; Silling G; Südhoff T; Ullmann AJ; Maschmeyer G
    Ann Hematol; 2009 Feb; 88(2):97-110. PubMed ID: 18853161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design of clinical trials of empiric antifungal therapy in patients with persistent febrile neutropenia: considerations and critiques.
    Sobel JD
    Pharmacotherapy; 2006 Jun; 26(6 Pt 2):47S-54S. PubMed ID: 16716122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in invasive fungal infections, with emphasis on invasive aspergillosis.
    Erjavec Z; Kluin-Nelemans H; Verweij PE
    Clin Microbiol Infect; 2009 Jul; 15(7):625-33. PubMed ID: 19673973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antifungal agents: mode of action in yeast cells.
    Carrillo-Muñoz AJ; Giusiano G; Ezkurra PA; Quindós G
    Rev Esp Quimioter; 2006 Jun; 19(2):130-9. PubMed ID: 16964330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of intracranial fungal infections in patients with haematological malignancies.
    Mattiuzzi G; Giles FJ
    Br J Haematol; 2005 Nov; 131(3):287-300. PubMed ID: 16225648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antifungal prophylaxis for invasive mycoses in high risk patients.
    Ullmann AJ; Cornely OA
    Curr Opin Infect Dis; 2006 Dec; 19(6):571-6. PubMed ID: 17075333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fungal respiratory disease.
    Yao Z; Liao W
    Curr Opin Pulm Med; 2006 May; 12(3):222-7. PubMed ID: 16582678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.